136 related articles for article (PubMed ID: 2294737)
1. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.
Kasiske BL; Velosa JA; Halstenson CE; La Belle P; Langendörfer A; Keane WF
Am J Kidney Dis; 1990 Jan; 15(1):8-15. PubMed ID: 2294737
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ
Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
Vega GL; Grundy SM
Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
[TBL] [Abstract][Full Text] [Related]
4. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
Forti N; Ramires JA
Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
[TBL] [Abstract][Full Text] [Related]
6. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR
Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
Golper TA; Illingworth DR; Morris CD; Bennett WM
Am J Kidney Dis; 1989 Apr; 13(4):312-20. PubMed ID: 2650539
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V.
Biesenbach G; Zazgornik J
Clin Nephrol; 1992 Jun; 37(6):274-9. PubMed ID: 1638777
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein (a).
Traindl O; Reading S; Franz M; Watschinger B; Klauser R; Pidlich H; Widhalm K; Pohanka E; Kovarik J
Nephron; 1992; 62(4):394-8. PubMed ID: 1300434
[TBL] [Abstract][Full Text] [Related]
11. Management of primary mixed hyperlipidemia with lovastatin.
Vega GL; Grundy SM
Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets.
Cobb MM; Teitelbaum HS; Breslow JL
JAMA; 1991 Feb; 265(8):997-1001. PubMed ID: 1992214
[TBL] [Abstract][Full Text] [Related]
13. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.
Bradford RH; Shear CL; Chremos AN; Dujovne C; Franklin FA; Hesney M; Higgins J; Langendörfer A; Pool JL; Schnaper H
Am J Cardiol; 1990 Sep; 66(8):44B-55B. PubMed ID: 2206036
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
[TBL] [Abstract][Full Text] [Related]
16. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
[TBL] [Abstract][Full Text] [Related]
17. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
Bradford RH; Shear CL; Chremos AN; Dujovne C; Downton M; Franklin FA; Gould AL; Hesney M; Higgins J; Hurley DP
Arch Intern Med; 1991 Jan; 151(1):43-9. PubMed ID: 1985608
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
[TBL] [Abstract][Full Text] [Related]
19. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
D'Agostino RB; Kannel WB; Stepanians MN; D'Agostino LC
Am J Cardiol; 1992 Jan; 69(1):28-34. PubMed ID: 1729864
[TBL] [Abstract][Full Text] [Related]
20. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil.
Groggel GC; Cheung AK; Ellis-Benigni K; Wilson DE
Kidney Int; 1989 Aug; 36(2):266-71. PubMed ID: 2779095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
